Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer

References

• Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–2020. doi:10.1016/S0140-6736(20)30974-0
   PubMed Web of Science ®Google Scholar
• Mohammed S, Van Buren G, Fisher WE. Pancreatic cancer: advances in treatment. World J Gastroenterol. 2014;20(28):9354–9360. doi:10.3748/wjg.v20.i28.9354
   PubMed Web of Science ®Google Scholar
• Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: a Review. J Am Med Assoc. 2021;326(9):851–862. doi:10.1001/jama.2021.13027
   PubMed Web of Science ®Google Scholar
• Faraoni I, Graziani G. Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. Cancers. 2018;10(12):487. doi:10.3390/cancers10120487
   PubMed Web of Science ®Google Scholar
• Zhu H, Wei M, Xu J, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020;34(9):987–1011. doi:10.1186/s12943-020-01167-9
   Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi:10.1056/NEJMOA1903387
   PubMed Web of Science ®Google Scholar
• Mensah LB, Morton SW, Li J, et al. Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer. Bioeng Transl Med. 2019;4(2):e10131. doi:10.1002/BTM2.10131
   PubMed Web of Science ®Google Scholar
• Du C, Qi Y, Zhang Y, et al. Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation. ACS Nano. 2018;12(11):10785–10796. doi:10.1021/acsnano.8b01573
   PubMed Web of Science ®Google Scholar
• Carvalho BG, Vit FF, Carvalho HF, Han SW, de la Torre LG. Recent advances in co-delivery nanosystems for synergistic action in cancer treatment. J Mater Chem B. 2021;9(5):1208–1237. doi:10.1039/D0TB02168G
   PubMed Web of Science ®Google Scholar
• Demiray M. Combinatorial therapy of high dose vitamin C and PARP inhibitors in DNA repair deficiency: a series of 8 patients. Integr Cancer Ther. 2020;19:1534735420969812. doi:10.1177/1534735420969812
   Web of Science ®Google Scholar
• Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al. O2⋅- and H2O2-mediated disruption of fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell. 2017;31(4):487–500. doi:10.1016/j.ccell.2017.02.018
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020;20(2):101–124. doi:10.1038/s41573-020-0090-8
   PubMed Web of Science ®Google Scholar
• Wang W, Xiong Y, Hu X, et al. Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity. Acta Biomater. 2023;157:428–441. doi:10.1016/j.actbio.2022.12.021
   PubMed Web of Science ®Google Scholar
• Gómez-Morales J, Iafisco M, Delgado-López JM, Sarda S, Drouet C. Progress on the preparation of nanocrystalline apatites and surface characterization: overview of fundamental and applied aspects. Prog Cryst Growth Charact Mater. 2013;59(1):1–46. doi:10.1016/j.pcrysgrow.2012.11.001
   Web of Science ®Google Scholar
• Oltolina F, Gregoletto L, Colangelo D, Gómez-Morales J, Delgado-López JM, Prat M. Monoclonal antibody-targeted fluorescein-5-isothiocyanate-labeled biomimetic nanoapatites: a promising fluorescent probe for imaging applications. Langmuir. 2015;31(5):1766–1775. doi:10.1021/la503747s
   PubMed Web of Science ®Google Scholar
• Khalifehzadeh R, Arami H. Biodegradable calcium phosphate nanoparticles for cancer therapy. Adv Colloid Interface Sci. 2020;279:102157. doi:10.1016/J.CIS.2020.102157
   PubMed Web of Science ®Google Scholar
• Guan Q, Zhou Le L, Lv FH, Li WY, Li YA, Dong Bin Y. A glycosylated covalent organic framework equipped with BODIPY and CaCO3 for synergistic tumor therapy. Angew Chemie Int Ed. 2020;59(41):18042–18047. doi:10.1002/anie.202008055
   PubMed Web of Science ®Google Scholar
• Chen J, Qiu M, Zhang S, et al. A calcium phosphate drug carrier loading with 5-fluorouracil achieving a synergistic effect for pancreatic cancer therapy. J Colloid Interface Sci. 2022;605:263–273. doi:10.1016/j.jcis.2021.07.080
   PubMed Web of Science ®Google Scholar
• Delgado-López JM, Iafisco M, Rodríguez I, Tampieri A, Prat M, Gómez-Morales J. Crystallization of bioinspired citrate-functionalized nanoapatite with tailored carbonate content. Acta Biomater. 2012;8(9):3491–3499. doi:10.1016/j.actbio.2012.04.046
   PubMed Web of Science ®Google Scholar
• Gallarate M, Carlotti ME, Trotta M, Bovo S. On the stability of ascorbic acid in emulsified systems for topical and cosmetic use. Int J Pharm. 1999;188(2):233–241. doi:10.1016/S0378-5173(99)00228-8
   PubMed Web of Science ®Google Scholar
• Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: analysis of collective cell migration using the wound healing assay. J Invest Dermatol. 2017;137(2):e11–e16. doi:10.1016/j.jid.2016.11.020
   PubMed Web of Science ®Google Scholar
• Thorsell A-G, Ekblad T, Karlberg T, et al. Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors. J Med Chem. 2017;60(4):1262–1271. doi:10.1021/acs.jmedchem.6b00990
   PubMed Web of Science ®Google Scholar
• Rodríguez-Ruiz I, Delgado-López JM, Durán-Olivencia MA, et al. PH-responsive delivery of doxorubicin from citrate-apatite nanocrystals with tailored carbonate content. Langmuir. 2013;29(26):8213–8221. doi:10.1021/la4008334
   PubMed Web of Science ®Google Scholar
• Iafisco M, Ramírez-Rodríguez GB, Sakhno Y, et al. The growth mechanism of apatite nanocrystals assisted by citrate: relevance to bone biomineralization. Cryst Eng Comm. 2015;17(3):507–511. doi:10.1039/c4ce01415d
   Google Scholar
• Yohannan Panicker C, Tresa Varghese H, Philip D. FT-IR, FT-Raman and SERS spectra of Vitamin C. Spectrochim Acta. 2006;65(3–4):802–804. doi:10.1016/j.saa.2005.12.044
   PubMed Web of Science ®Google Scholar
• Novo B, Bonanomi J, De Fiore S, Calogero F. Crystalline and amorphous forms of olaparib; 2017.
   Google Scholar
• Delgado-López JM, Frison R, Cervellino A, Gómez-Morales J, Guagliardi A, Masciocchi N. Crystal size, morphology, and growth mechanism in bio-inspired apatite nanocrystals. Adv Funct Mater. 2014;24:1090–1099. doi:10.1002/adfm.201302075
   Web of Science ®Google Scholar
• Bruschi M. Mathematical models of drug release. In: Strategies to Modify the Drug Release from Pharmaceutical Systems. Elsevier; 2015:63–86. doi:10.1016/b978-0-08-100092-2.00005-9
   Google Scholar
• Hu H, Zhang Y, Ji W, et al. Hyaluronic acid-coated and Olaparib-loaded PEI − PLGA nanoparticles for the targeted therapy of triple negative breast cancer. J Microencapsul. 2021;39(1):25–36. doi:10.1080/02652048.2021.2014586
   PubMed Web of Science ®Google Scholar
• Novohradsky V, Zajac J, Vrana O, Kasparkova J, Brabec V. Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells. Oncotarget. 2018;9(47):28456–28473. doi:10.18632/oncotarget.25466
   PubMedGoogle Scholar
• Caster JM, Sethi M, Kowalczyk S, et al. Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. Nanoscale. 2015;7(6):2805–2811. doi:10.1039/c4nr07102f
   PubMed Web of Science ®Google Scholar
• Van De Ven AL, Tangutoori S, Baldwin P, et al. Nanoformulation of olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation. Mol Cancer Ther. 2017;16(7):1279–1289. doi:10.1158/1535-7163.MCT-16-0740
   PubMed Web of Science ®Google Scholar
• Ma Y, Chen P, Drisko J, Khabele D, Godwin A, Chen Q. Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer. Oncol Lett. 2020;19(4):2629–2638. doi:10.3892/ol.2020.11364
   PubMed Web of Science ®Google Scholar
• Mesas C, Garcés V, Martínez R, et al. Colon cancer therapy with calcium phosphate nanoparticles loading bioactive compounds from Euphorbia lathyris: in vitro and in vivo assay. Bio Pharmacr. 2022;155:113723. doi:10.1016/j.biopha.2022.113723
   Google Scholar
• Iafisco M, Delgado-Lopez JM, Varoni EM, et al. Cell surface receptor targeted biomimetic apatite nanocrystals for cancer therapy. Small. 2013;9(22):3834–3844. doi:10.1002/smll.201202843
   PubMed Web of Science ®Google Scholar
• Buranasudja V, Doskey CM, Gibson AR, et al. Pharmacologic ascorbate primes pancreatic cancer cells for death by rewiring cellular energetics and inducing DNA damage. Mol Cancer Res. 2019;17(10):2102–2114. doi:10.1158/1541-7786.MCR-19-0381
   PubMed Web of Science ®Google Scholar
• Mao X, Du S, Yang Z, et al. Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro. Mol Med Rep. 2017;16(1):208–214. doi:10.3892/MMR.2017.6568
   PubMed Web of Science ®Google Scholar
• Prasad CB, Prasad SB, Yadav SS, et al. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep. 2017;7(1):1–15. doi:10.1038/s41598-017-13232-3
   PubMedGoogle Scholar
• Quiñonero F, Mesas C, Muñoz-Gámez JA, et al. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine. Bio Pharmacr. 2022;155:113669. doi:10.1016/j.biopha.2022.113669
   Google Scholar
• Roy I, McAllister DM, Gorse E, et al. Pancreatic cancer cell migration and metastasis is regulated by chemokine-biased agonism and bioenergetic signaling. Cancer Res. 2015;75(17):3529–3542. doi:10.1158/0008-5472.CAN-14-2645
   PubMed Web of Science ®Google Scholar
• Li D, Hu C, Yang J, et al. Enhanced anti-cancer effect of folate-conjugated olaparib nanoparticles combined with radiotherapy in cervical carcinoma. Int J Nanomedicine. 2020;15:10045–10058. doi:10.2147/IJN.S272730
   PubMed Web of Science ®Google Scholar
• Nakamura N, Fujihara H, Kawaguchi K, et al. Possible action of olaparib for preventing invasion of oral squamous cell carcinoma in vitro and in vivo. Int J Mol Sci. 2022;23(5):2527. doi:10.3390/ijms23052527
   PubMed Web of Science ®Google Scholar
• Wu M, Liu J, Hu C, et al. Olaparib nanoparticles potentiated radiosensitization effects on lung cancer. Int J Nanomedicine. 2018;13:8461–8472. doi:10.2147/IJN.S181546
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hu H, Tang W, et al. A multifunctional magnetic nanosystem based on “two strikes” effect for synergistic anticancer therapy in triple-negative breast cancer. J Control Release. 2020;322:401–415. doi:10.1016/j.jconrel.2020.03.036
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410. doi:10.1038/s41467-018-03705-y
   PubMed Web of Science ®Google Scholar
• Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C. 2019;98:1252–1276. doi:10.1016/j.msec.2019.01.066
   PubMed Web of Science ®Google Scholar
• Min KH, Lee HJ, Kim K, Kwon IC, Jeong SY, Lee SC. The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles. Biomaterials. 2012;33(23):5788–5797. doi:10.1016/j.biomaterials.2012.04.057
   PubMed Web of Science ®Google Scholar
• Kang Y, Sun W, Li S, et al. Oligo hyaluronan‐coated silica/hydroxyapatite degradable nanoparticles for targeted cancer treatment. Adv Sci. 2019;6(13):1900716. doi:10.1002/advs.201900716
   Web of Science ®Google Scholar
• Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011;71(14):5020–5029. doi:10.1158/0008-5472.CAN-11-0908
   PubMed Web of Science ®Google Scholar
• Grapa CM, Mocan T, Gonciar D, et al. Epidermal growth factor receptor and its role in pancreatic cancer treatment mediated by nanoparticles. Int J Nanomedicine. 2019;14:9693–9706. doi:10.2147/IJN.S226628
   PubMed Web of Science ®Google Scholar
• Chen H, Bian A, Yang L, et al. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression. Oncogene. 2021;40(8):1440–1457. doi:10.1038/s41388-020-01626-z
   PubMed Web of Science ®Google Scholar
• Sokolova V, Epple M. Biological and medical applications of calcium phosphate nanoparticles. Chem Eur J. 2021;27(27):7471–7488. doi:10.1002/chem.202005257
   PubMed Web of Science ®Google Scholar
• Epple M. Review of potential health risks associated with nanoscopic calcium phosphate. Acta Bio. 2018;77:1–14. doi:10.1016/j.actbio.2018.07.036
   PubMed Web of Science ®Google Scholar
• Sandhöfer B, Meckel M, Delgado-López JM, et al. Synthesis and preliminary in vivo evaluation of well-dispersed biomimetic nanocrystalline apatites labeled with positron emission tomographic imaging agents. ACS Appl Mater Interfaces. 2015;7(19):10623–10633. doi:10.1021/acsami.5b02624
   PubMed Web of Science ®Google Scholar